Case series of pleomorphic carcinomas of the lung treated with nivolumab.Pleomorphic carcinoma (PC) of the lung is a rare type of non-small cell lung cancer, exhibiting aggressive behavior and resistance to chemotherapy and radiotherapy.  We retrospectively reviewed the clinical records of three patients with PC of the lung treated with nivolumab: a 59-year-old woman (Case 1), a 66-year-old man (Case 2), and an 83-year-old man (Case 3).  However, in Case 2, brain and bone metastases progressed during nivolumab treatment in spite of high PD-L1 expression.  This case series indicates that nivolumab is effective to some extent for PC of the lung.  However, the clinical course of patients treated with nivolumab should be carefully observed, even when PD-L1 is highly expressed.
nivolumab
Case series of pleomorphic carcinomas of the lung treated with nivolumab.Pleomorphic carcinoma (PC) of the lung is a rare type of non-small cell lung cancer, exhibiting aggressive behavior and resistance to chemotherapy and radiotherapy.  We retrospectively reviewed the clinical records of three patients with PC of the lung treated with nivolumab: a 59-year-old woman (Case 1), a 66-year-old man (Case 2), and an 83-year-old man (Case 3).  However, in Case 2, brain and bone metastases progressed during nivolumab treatment in spite of high PD-L1 expression.  This case series indicates that nivolumab is effective to some extent for PC of the lung.  However, the clinical course of patients treated with nivolumab should be carefully observed, even when PD-L1 is highly expressed.
nivolumab
Case series of pleomorphic carcinomas of the lung treated with nivolumab.Pleomorphic carcinoma (PC) of the lung is a rare type of non-small cell lung cancer, exhibiting aggressive behavior and resistance to chemotherapy and radiotherapy.  We retrospectively reviewed the clinical records of three patients with PC of the lung treated with nivolumab: a 59-year-old woman (Case 1), a 66-year-old man (Case 2), and an 83-year-old man (Case 3).  However, in Case 2, brain and bone metastases progressed during nivolumab treatment in spite of high PD-L1 expression.  This case series indicates that nivolumab is effective to some extent for PC of the lung.  However, the clinical course of patients treated with nivolumab should be carefully observed, even when PD-L1 is highly expressed.
nivolumab
Case series of pleomorphic carcinomas of the lung treated with nivolumab.Pleomorphic carcinoma (PC) of the lung is a rare type of non-small cell lung cancer, exhibiting aggressive behavior and resistance to chemotherapy and radiotherapy.  We retrospectively reviewed the clinical records of three patients with PC of the lung treated with nivolumab: a 59-year-old woman (Case 1), a 66-year-old man (Case 2), and an 83-year-old man (Case 3).  However, in Case 2, brain and bone metastases progressed during nivolumab treatment in spite of high PD-L1 expression.  This case series indicates that nivolumab is effective to some extent for PC of the lung.  However, the clinical course of patients treated with nivolumab should be carefully observed, even when PD-L1 is highly expressed.
nivolumab